Synteract’s Francoise Desir Named to the PharmaVOICE 100 — The Most Inspiring People in Life Sciences
Published: Aug 01, 2018
Respected team leader and motivator recognized for her passion and dedication in bringing clinical trials to life
SAN DIEGO & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services enabling biopharma companies to bring new medicines to market, congratulates Francoise Desir, project director at Synteract, for being named one of the 2018 PharmaVOICE 100. PharmaVOICE magazine releases the list of the 100 most inspiring people in the life sciences industry annually, identifying industry thought leaders and innovators who have the biggest impact in their fields. This year marks the sixth that Synteract leaders have made the list.
Francoise Desir inspires people daily as she makes improving people’s lives her mission, both personally and professionally. With more than a decade of experience managing and helping global teams complete complex drug development projects, she prioritizes the needs of her clients, coordinating and managing clinical trials from start up through close out.
Professionally, she exceeds expectations daily and is fueled by the dedication and commitment of the colleagues and customers she works with to develop needed treatments, as well as by the doctors and patients she encounters who describe to her the positive impact they have witnessed as a result of clinical research. In addition, from a personal perspective, her most memorable vacation was to Africa to help a medical clinic in need. She travelled with members of her family to donate medical supplies, and other basic healthcare necessities. “We felt it was a small act, but the impact was significant,” Desir says.
“Francoise Desir is a respected and determined member of the Synteract team. She’s always focused on delivering a successful outcome to our customers and on managing the complexities surrounding the global clinical trials we undertake. She leads and inspires her team every day as she demonstrates the passion and commitment she has to help others. We congratulate her on this well-deserved award,” said Steve Powell, CEO. “Francoise embodies the spirit that helps us all bring clinical trials to life, and we are very proud she is part of our Synteract team.”
The PharmaVOICE 100 has become a hallmark for the life sciences industry. Every year, thousands of nominations are submitted to PharmaVOICE by colleagues who believe their nominee fits the required criteria of providing inspiration to peers, coworkers, and companies through their innovative and motivational approaches to addressing the industry’s challenges.
According to the magazine, “The PharmaVOICE 100 develop breakthrough strategies, products and services. They are known for pioneering new paths and lifting their companies to new heights. They also take the time to mentor the next generation of industry leaders.” The full list of honorees is showcased in the August 2018 issue of the magazine.
“As we move through life’s journey, our days are quickly filled with activity, most of it important in providing and caring for ourselves and our families. I have learned that we have the capacity to stretch beyond ourselves and that which consumes us day in and day out, and the reward is greater to those who give than for those who receive,” says Desir. “I know what I do, what we all do in this industry, improves lives…and my trip to Africa brought it full circle. We have the ability to make a difference; each one of us CAN make a difference…we can change lives.”
With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology, dermatology, and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies.
Hilary McCarthy, 508-829-2543